Menu Search
Equities

Cabaletta Bio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CABA*:MEX

Cabaletta Bio Inc

Actions
  • Price (MXN)31.53
  • Today's Change-13.27 / -29.62%
  • Shares traded--
  • 1 Year change--
  • Beta3.2980
Data delayed at least 20 minutes, as of Aug 08 2024 12:30 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

  • Revenue in USD (TTM)0.00
  • Net income in USD-158.52m
  • Incorporated2017
  • Employees148.00
  • Location
    Cabaletta Bio Inc2929 Arch Street, Suite 600PHILADELPHIA 19104United StatesUSA
  • Phone+1 (267) 759-3100
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cabalettabio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.